CLINUVEL PHARMACEUTICALS LIMITED - Announcements

0.16%

$12.22

Market Cap $612.5M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	Media Release- Clinuvel successful in US Phase III trial	PRICE SENSITIVE	11/11/13	135.4KB	Share
CUV	Clinical significance and benefit from SCENESSE in US Phase	PRICE SENSITIVE	11/11/13	148.25KB	Share
CUV	Clinuvel to start a Phase II vitiligo study in Singapore	PRICE SENSITIVE	04/11/13	157.94KB	Share
CUV	Positive pilot data published on SCENESSE in HHD		28/10/13	124KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/13	149.95KB	Share
CUV	Annual Report to shareholders		11/10/13	1.65MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		11/10/13	653.51KB	Share
CUV	AGM Date		20/09/13	214.71KB	Share
CUV	Becoming a substantial holder		17/09/13	240.24KB	Share
CUV	Five month study follow up - SCENESSE in vitiligo (CUV102)	PRICE SENSITIVE	02/09/13	132.73KB	Share
CUV	Preliminary Final Report	PRICE SENSITIVE	28/08/13	640.94KB	Share
CUV	Letter from the CEO		05/08/13	84.05KB	Share
CUV	EMA review of SCENESSE extended to January 2014		01/08/13	254.17KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	149.21KB	Share
CUV	Letter from the CEO		18/06/13	154.28KB	Share
CUV	Clinuvel Newsletter		18/06/13	510.38KB	Share
CUV	s.708A Notice		16/05/13	34.48KB	Share
CUV	Appendix 3B and Lapse of Unlisted Conditional Rights		15/05/13	488.57KB	Share
CUV	Reinstatement to Official Quotation	PRICE SENSITIVE	06/05/13	77.18KB	Share
CUV	Placement	PRICE SENSITIVE	06/05/13	318.57KB	Share
CUV	Suspension Request		03/05/13	194.14KB	Share
CUV	Suspension from Official Quotation	PRICE SENSITIVE	03/05/13	76.89KB	Share
CUV	Trading Halt Request		01/05/13	157.77KB	Share
CUV	Trading Halt	PRICE SENSITIVE	01/05/13	78.08KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/13	172.06KB	Share
CUV	Clinuvel Newsletter		09/04/13	467.64KB	Share
CUV	Appendix 3B and Lapse of Unlisted Conditional Rights		04/03/13	493.7KB	Share
CUV	SCENESSE to be presented at leading academic meetings		01/03/13	120.51KB	Share
CUV	Clinuvel clears EMA manufacturing audit	PRICE SENSITIVE	28/02/13	117.6KB	Share
CUV	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/13	3.13MB	Share
CUV	Clinuvel Newsletter		21/02/13	504.41KB	Share
CUV	Change of Director's Interest Notice		08/02/13	649.69KB	Share
CUV	Appendix 3B		23/01/13	458.28KB	Share
CUV	Clinuvel Corporate Update Presentation		21/01/13	906.78KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/13	172.11KB	Share
CUV	Presentation- Clinical Study Results - US Phase IIa Vitiligo		19/12/12	1.25MB	Share
CUV	SCENESSE successful in Phase IIa vitiligo study	PRICE SENSITIVE	19/12/12	142.87KB	Share
CUV	Appendix 3B and Lapse of Unlisted Conditional Rights		11/12/12	494.78KB	Share
CUV	Results of Meeting		20/11/12	221.71KB	Share
CUV	CEO's AGM Presentation		20/11/12	2.16MB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	22/10/12	139.09KB	Share
CUV	Annual Report to shareholders		19/10/12	1.29MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		19/10/12	647.38KB	Share
CUV	Observations from Clinuvel's US vitiligo study published	PRICE SENSITIVE	16/10/12	145.39KB	Share
CUV	Final Director's Interest Notice		03/10/12	110.13KB	Share
CUV	Annual General Meeting Date		02/10/12	79.81KB	Share
CUV	Management change and regulatory review update	PRICE SENSITIVE	01/10/12	144.41KB	Share
CUV	Dr Helmer Agersborg		28/09/12	54.78KB	Share
CUV	Preliminary Final Report	PRICE SENSITIVE	29/08/12	810.68KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	137.6KB	Share
CUV	s.708A Notice		10/07/12	39.5KB	Share
CUV	Clinuvel Newsletter - July 2012		03/07/12	208.68KB	Share
CUV	Change of Director's Interest Notice		03/07/12	194.8KB	Share
CUV	Appendix 3B		02/07/12	461.76KB	Share
CUV	Placement	PRICE SENSITIVE	25/06/12	315.77KB	Share
CUV	Trading Halt Request		21/06/12	153.57KB	Share
CUV	Trading Halt	PRICE SENSITIVE	21/06/12	79.16KB	Share
CUV	Appendix 3B and Lapse of Unlisted Conditional Rights		04/06/12	496.37KB	Share
CUV	Clinuvel commences US Phase III trial of SCENESSE	PRICE SENSITIVE	22/05/12	153.61KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	136.27KB	Share
CUV	Swiss insurers agree to reimburse Clinuvel's SCENESSE	PRICE SENSITIVE	26/04/12	147.97KB	Share
CUV	Clinuvel Newsletter - April 2012		03/04/12	525.18KB	Share
CUV	Clinuvel Corporate Update Presentation		21/03/12	901.02KB	Share
CUV	Appendix 3B		16/03/12	177.24KB	Share
CUV	Clinuvel, FDA agree in principle to Phase III study	PRICE SENSITIVE	15/03/12	115.62KB	Share
CUV	Observations from Clinuvel's programs being presented at AAD	PRICE SENSITIVE	15/03/12	2.2MB	Share
CUV	Clinuvel Newsletter - February 2012	PRICE SENSITIVE	29/02/12	650.99KB	Share
CUV	Appendix 4D - Half Yearly Report	PRICE SENSITIVE	24/02/12	791.23KB	Share
CUV	Lapse and Forfeit of Unlisted Share Options		13/02/12	196.79KB	Share
CUV	Clinuvel files European MAA for SCENESSE (afamelanotide)	PRICE SENSITIVE	06/02/12	115.36KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	135.95KB	Share
CUV	Appendix 3B		16/01/12	237.78KB	Share
CUV	Response to ASX price query	PRICE SENSITIVE	13/01/12	497.41KB	Share
CUV	Clinuvel - positive results from pivotal Phase III EPP study	PRICE SENSITIVE	20/12/11	89.71KB	Share
CUV	Encouraging interim safety results in Phase II OTR study	PRICE SENSITIVE	15/12/11	82.23KB	Share
CUV	Appendix 3B		12/12/11	233.77KB	Share
CUV	Change of Director's Interest Notice x 4		17/11/11	315.8KB	Share
CUV	Appendix 3B and Lapse of Conditional Performance Rights		17/11/11	745.02KB	Share
CUV	Results of Meeting		09/11/11	363.82KB	Share
CUV	Clinuvel AGM 2011 CEO Presentation		09/11/11	1.66MB	Share
CUV	Clinuvel granted US topical formulation patent	PRICE SENSITIVE	08/11/11	63.69KB	Share
CUV	Media release - US Phase II results	PRICE SENSITIVE	03/11/11	87.42KB	Share
CUV	Clinuvel announces positive results of Phase II US study	PRICE SENSITIVE	03/11/11	86.84KB	Share
CUV	Amendment to Change of Director's Interest Notice		26/10/11	416.27KB	Share
CUV	First positive observations from Clinuvel's vitiligo trial	PRICE SENSITIVE	21/10/11	222.66KB	Share
CUV	Clinuvel Newsletter October 2011		14/10/11	353.35KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	14/10/11	151.95KB	Share
CUV	Annual Report to shareholders		07/10/11	5.79MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		07/10/11	470.85KB	Share
CUV	AGM Date		22/09/11	16.86KB	Share
CUV	Change of Director's Interest Notice		20/09/11	253.36KB	Share
CUV	Appendix 3B		19/09/11	242.16KB	Share
CUV	Clinuvel completes pre-clinical program for SCENESSE	PRICE SENSITIVE	31/08/11	24.63KB	Share
CUV	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	25/08/11	1.84MB	Share
CUV	Lapse and Forfeit of Share Options and Conditional Rights		19/08/11	15.41KB	Share
CUV	Letter to Shareholders		29/07/11	38.85KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/11	195.83KB	Share
CUV	Clinuvel Corporate Update Presentation		26/07/11	9.65MB	Share
CUV	Clinuvel records first A$1 million in sales	PRICE SENSITIVE	23/06/11	21.63KB	Share
CUV	Clinuvel investor update presentation		09/06/11	2.74MB	Share

CUVMedia Release- Clinuvel successful in US Phase III trial
11/11/13	PRICE SENSITIVE	135.4KB	Share
CUVClinical significance and benefit from SCENESSE in US Phase
11/11/13	PRICE SENSITIVE	148.25KB	Share
CUVClinuvel to start a Phase II vitiligo study in Singapore
04/11/13	PRICE SENSITIVE	157.94KB	Share
CUVPositive pilot data published on SCENESSE in HHD
28/10/13		124KB	Share
CUVAppendix 4C - quarterly
28/10/13	PRICE SENSITIVE	149.95KB	Share
CUVAnnual Report to shareholders
11/10/13		1.65MB	Share
CUVNotice of Annual General Meeting/Proxy Form
11/10/13		653.51KB	Share
CUVAGM Date
20/09/13		214.71KB	Share
CUVBecoming a substantial holder
17/09/13		240.24KB	Share
CUVFive month study follow up - SCENESSE in vitiligo (CUV102)
02/09/13	PRICE SENSITIVE	132.73KB	Share
CUVPreliminary Final Report
28/08/13	PRICE SENSITIVE	640.94KB	Share
CUVLetter from the CEO
05/08/13		84.05KB	Share
CUVEMA review of SCENESSE extended to January 2014
01/08/13		254.17KB	Share
CUVAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	149.21KB	Share
CUVLetter from the CEO
18/06/13		154.28KB	Share
CUVClinuvel Newsletter
18/06/13		510.38KB	Share
CUVs.708A Notice
16/05/13		34.48KB	Share
CUVAppendix 3B and Lapse of Unlisted Conditional Rights
15/05/13		488.57KB	Share
CUVReinstatement to Official Quotation
06/05/13	PRICE SENSITIVE	77.18KB	Share
CUVPlacement
06/05/13	PRICE SENSITIVE	318.57KB	Share
CUVSuspension Request
03/05/13		194.14KB	Share
CUVSuspension from Official Quotation
03/05/13	PRICE SENSITIVE	76.89KB	Share
CUVTrading Halt Request
01/05/13		157.77KB	Share
CUVTrading Halt
01/05/13	PRICE SENSITIVE	78.08KB	Share
CUVAppendix 4C - quarterly
24/04/13	PRICE SENSITIVE	172.06KB	Share
CUVClinuvel Newsletter
09/04/13		467.64KB	Share
CUVAppendix 3B and Lapse of Unlisted Conditional Rights
04/03/13		493.7KB	Share
CUVSCENESSE to be presented at leading academic meetings
01/03/13		120.51KB	Share
CUVClinuvel clears EMA manufacturing audit
28/02/13	PRICE SENSITIVE	117.6KB	Share
CUVHalf Yearly Report and Accounts
27/02/13	PRICE SENSITIVE	3.13MB	Share
CUVClinuvel Newsletter
21/02/13		504.41KB	Share
CUVChange of Director's Interest Notice
08/02/13		649.69KB	Share
CUVAppendix 3B
23/01/13		458.28KB	Share
CUVClinuvel Corporate Update Presentation
21/01/13		906.78KB	Share
CUVAppendix 4C - quarterly
21/01/13	PRICE SENSITIVE	172.11KB	Share
CUVPresentation- Clinical Study Results - US Phase IIa Vitiligo
19/12/12		1.25MB	Share
CUVSCENESSE successful in Phase IIa vitiligo study
19/12/12	PRICE SENSITIVE	142.87KB	Share
CUVAppendix 3B and Lapse of Unlisted Conditional Rights
11/12/12		494.78KB	Share
CUVResults of Meeting
20/11/12		221.71KB	Share
CUVCEO's AGM Presentation
20/11/12		2.16MB	Share
CUVAppendix 4C - quarterly
22/10/12	PRICE SENSITIVE	139.09KB	Share
CUVAnnual Report to shareholders
19/10/12		1.29MB	Share
CUVNotice of Annual General Meeting/Proxy Form
19/10/12		647.38KB	Share
CUVObservations from Clinuvel's US vitiligo study published
16/10/12	PRICE SENSITIVE	145.39KB	Share
CUVFinal Director's Interest Notice
03/10/12		110.13KB	Share
CUVAnnual General Meeting Date
02/10/12		79.81KB	Share
CUVManagement change and regulatory review update
01/10/12	PRICE SENSITIVE	144.41KB	Share
CUVDr Helmer Agersborg
28/09/12		54.78KB	Share
CUVPreliminary Final Report
29/08/12	PRICE SENSITIVE	810.68KB	Share
CUVAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	137.6KB	Share
CUVs.708A Notice
10/07/12		39.5KB	Share
CUVClinuvel Newsletter - July 2012
03/07/12		208.68KB	Share
CUVChange of Director's Interest Notice
03/07/12		194.8KB	Share
CUVAppendix 3B
02/07/12		461.76KB	Share
CUVPlacement
25/06/12	PRICE SENSITIVE	315.77KB	Share
CUVTrading Halt Request
21/06/12		153.57KB	Share
CUVTrading Halt
21/06/12	PRICE SENSITIVE	79.16KB	Share
CUVAppendix 3B and Lapse of Unlisted Conditional Rights
04/06/12		496.37KB	Share
CUVClinuvel commences US Phase III trial of SCENESSE
22/05/12	PRICE SENSITIVE	153.61KB	Share
CUVAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	136.27KB	Share
CUVSwiss insurers agree to reimburse Clinuvel's SCENESSE
26/04/12	PRICE SENSITIVE	147.97KB	Share
CUVClinuvel Newsletter - April 2012
03/04/12		525.18KB	Share
CUVClinuvel Corporate Update Presentation
21/03/12		901.02KB	Share
CUVAppendix 3B
16/03/12		177.24KB	Share
CUVClinuvel, FDA agree in principle to Phase III study
15/03/12	PRICE SENSITIVE	115.62KB	Share
CUVObservations from Clinuvel's programs being presented at AAD
15/03/12	PRICE SENSITIVE	2.2MB	Share
CUVClinuvel Newsletter - February 2012
29/02/12	PRICE SENSITIVE	650.99KB	Share
CUVAppendix 4D - Half Yearly Report
24/02/12	PRICE SENSITIVE	791.23KB	Share
CUVLapse and Forfeit of Unlisted Share Options
13/02/12		196.79KB	Share
CUVClinuvel files European MAA for SCENESSE (afamelanotide)
06/02/12	PRICE SENSITIVE	115.36KB	Share
CUVAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	135.95KB	Share
CUVAppendix 3B
16/01/12		237.78KB	Share
CUVResponse to ASX price query
13/01/12	PRICE SENSITIVE	497.41KB	Share
CUVClinuvel - positive results from pivotal Phase III EPP study
20/12/11	PRICE SENSITIVE	89.71KB	Share
CUVEncouraging interim safety results in Phase II OTR study
15/12/11	PRICE SENSITIVE	82.23KB	Share
CUVAppendix 3B
12/12/11		233.77KB	Share
CUVChange of Director's Interest Notice x 4
17/11/11		315.8KB	Share
CUVAppendix 3B and Lapse of Conditional Performance Rights
17/11/11		745.02KB	Share
CUVResults of Meeting
09/11/11		363.82KB	Share
CUVClinuvel AGM 2011 CEO Presentation
09/11/11		1.66MB	Share
CUVClinuvel granted US topical formulation patent
08/11/11	PRICE SENSITIVE	63.69KB	Share
CUVMedia release - US Phase II results
03/11/11	PRICE SENSITIVE	87.42KB	Share
CUVClinuvel announces positive results of Phase II US study
03/11/11	PRICE SENSITIVE	86.84KB	Share
CUVAmendment to Change of Director's Interest Notice
26/10/11		416.27KB	Share
CUVFirst positive observations from Clinuvel's vitiligo trial
21/10/11	PRICE SENSITIVE	222.66KB	Share
CUVClinuvel Newsletter October 2011
14/10/11		353.35KB	Share
CUVAppendix 4C - quarterly
14/10/11	PRICE SENSITIVE	151.95KB	Share
CUVAnnual Report to shareholders
07/10/11		5.79MB	Share
CUVNotice of Annual General Meeting/Proxy Form
07/10/11		470.85KB	Share
CUVAGM Date
22/09/11		16.86KB	Share
CUVChange of Director's Interest Notice
20/09/11		253.36KB	Share
CUVAppendix 3B
19/09/11		242.16KB	Share
CUVClinuvel completes pre-clinical program for SCENESSE
31/08/11	PRICE SENSITIVE	24.63KB	Share
CUVAppendix 4E - Preliminary Final Report
25/08/11	PRICE SENSITIVE	1.84MB	Share
CUVLapse and Forfeit of Share Options and Conditional Rights
19/08/11		15.41KB	Share
CUVLetter to Shareholders
29/07/11		38.85KB	Share
CUVAppendix 4C - quarterly
27/07/11	PRICE SENSITIVE	195.83KB	Share
CUVClinuvel Corporate Update Presentation
26/07/11		9.65MB	Share
CUVClinuvel records first A$1 million in sales
23/06/11	PRICE SENSITIVE	21.63KB	Share
CUVClinuvel investor update presentation
09/06/11		2.74MB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.22		Change 0.020(0.16%)		Mkt cap ! $612.5M

Open	High	Low	Value	Volume
$12.14	$12.36	$12.10	$558.7K	45.71K

Buyers (Bids)

No.	Vol.	Price($)
1	50	$12.15

Sellers (Offers)

Price($)	Vol.	No.
$12.37	433	1

View Market Depth

No.	Vol.	Price($)
1	100	12.140
2	2282	12.050
4	1401	12.000
2	3674	11.970
3	924	11.900

Price($)	Vol.	No.
12.370	433	1
12.440	800	1
12.450	100	1
12.750	48	1
12.800	600	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories